Ticagrelor and Peripheral Arterial Disease

• Status: Terminated
• Trial end date: 2017-01-17
• Target enrollment: 0
• Participant gender: All

Summary

This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arkansas Heart Hospital
• Collaborators: The University of Texas Health Science Center at San Antonio; University of Alabama at Birmingham
• Treatments: Aspirin; Clopidogrel; Ticagrelor

Criteria

Inclusion Criteria:

• Patients with lower extremity claudication and PAD due to significant SFA stenosis (>60%) or total occlusions (Rutherford 2-6) that affects the quality of life despite medical therapy.

• The presence of OCT identified clot in the Superficial Femoral Artery (SFA) following stent placement.

• Evidence of significant SFA disease involving the most symptomatic limb established by noninvasive vascular testing (ankle-brachial index [ABI] <0.9, toe brachial Index [TBI] of <0.6. If ABI>1.4, SFA systolic acceleration time >140 milliseconds); computed tomographic angiography, or magnetic resonance angiography confirming at least a 60% stenosis of the SFA.

• At least one non-treated Below The Knee (BTK) vessel patent

• Male and female outpatients 18 years of age.

• The only following devices may be used for the revascularization procedures:

conventional balloons and bare metal stents (block randomization).

• Subject has been advised of the beneficial effects of smoking cessation and regular exercise but must not be in the process of changing their smoking status at the time of screening. Patients may resume or increase exercising as an effect of post procedurally improved lower limb perfusion.

• Peak Walking Time (PWT) limited only by claudication.

• Willingness to participate, documented by written informed consent.

Exclusion Criteria:

• Patients requiring dual anti-platelet drug treatment before start of study

• Planned amputation

• Use of atherectomy devices

• Hypersensitivity to acetylsalicylic acid, or ticagrelor. For ticagrelor, hypersensitivity reactions in the past include angioedema

• Patients with known bleeding disorders

• Patients with known active pathological bleeding

• Patients needing chronic oral anticoagulant maintenance therapy

• Patients with a history of intracranial hemorrhage at any time, GI bleed in the past 6 months, or major surgery within the past 30 days

• Ischemic stroke during the past 3 months

• Patients considered to be at risk of bradycardic events unless treated with a permanent pacemaker

• Target is a restenotic lesion or in-stent restenosis

• Any scheduled revascularization procedure requiring dual-anti-platelet therapy for more than one month

• Severe hypertension that may put the patient at risk, systolic greater than or equal to 180 and/or diastolic greater than or equal to 100

• Severe liver disease

• History of congestive heart failure with an Left Ventricular Ejection Fraction (LVEF) of less than 30%

• Concern for inability of the patient to comply with study procedures and/or follow up (eg, alcohol or drug abuse)

• Infra-popliteal disease involving the last remaining vessel (single run-off)

• Prior lower extremity revascularization within the past 30 days prior to enrollment

• Atherectomy of PAD

• EXCIPIENTS to ticagrelor hypersensitivity

• Known pregnancy, breast-feeding, or intend to become pregnant during the study period (all female patients 55 years and younger, without past history of hysterectomy must have a pregnancy test prior to peripheral intervention at baseline and at 6 months)

• Creatinine clearance < 30 mL/min